We're excited to announce that Medical Oncologist Dr Devika Das is joining us direct from WCLC 2025 to share her perspectives on the latest data in oncogene-addicted non-small cell lung cancer (NSCLC).
Dr Das is expected to review data from the following studies:
- Global TRUST-II: Updated efficacy and safety of taletrectinib in patients with ROS1+ NSCLC: The Global TRUST-II Study. Liu G, et al. Abstract MA02.02, WCLC 2025
- SHERLOCK: Primary endpoint results from SHERLOCK: a phase 2 trial of sotorasib, bevacizumab and chemotherapy in advanced KRAS G12C NSCLC. Lee C. K, et al. Abstract OA03.04, WCLC 2025
- REZILIENT1: Zipalertinib in NSCLC patients with EGFR exon 20 insertion mutations who received prior amivantamab. Piotrowska Z, et al. Abstract MA08.02, WCLC 2025
- Beamion LUNG-1: Zongertinib in patients with previously treated HER2-mutant NSCLC and brain metastases at baseline: Beamion LUNG-1. Ruiter G, et al. Abstract PT2.12.03, WCLC 2025
- SOHO-01: Factors associated with clinical outcomes in patients with HER2-mutant NSCLC treated with sevabertinib (BAY 2927088). Le X, et al. Abstract P3.12.41, WCLC 2025
How will these developments impact the management of oncogene-addicted NSCLC? Check back soon to find out!